Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M-Strong PG
- Development stage
- Unknown
- Lead developer
- Lloyd Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
M-Strong PG is a fixed-dose combination pharmaceutical product developed and marketed by Lloyd Healthcare, primarily indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. The formulation contains two active ingredients: pregabalin (75 mg) and methylcobalamin (750 mcg). Pregabalin is a gabapentinoid that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, which reduces the calcium-dependent release of excitatory neurotransmitters such as glutamate and substance P. Methylcobalamin, a coenzyme form of Vitamin B12, acts as a cofactor for the enzyme methionine synthase, facilitating the conversion of homocysteine to methionine and supporting the synthesis of phospholipids required for myelin sheath regeneration and nerve repair. Although Lloyd Healthcare categorizes this product within its cardio-diabetic portfolio, M-Strong PG is specifically used for the neurological complications of diabetes rather than the direct treatment of cardiovascular disease or glycemic control.
- Brand names
- M-Strong PG
- Other names
- Pregabalin + Methylcobalamin
02
Targets
α2δ (Voltage-gated calcium channel alpha-2-delta subunit)MTR (Methionine synthase)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on M-Strong PG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M-Strong PG.